The legal and political fallout of the pandemic is still being actively contested in the highest chambers of European justice. In a highly anticipated development, a senior adviser to the European Union’s highest court has recommended the complete dismissal of an appeal filed by the European Commission. The Commission’s appeal sought to overturn a landmark lower-court ruling ordering the disclosure of heavily redacted information and contracts related to the purchase of COVID-19 vaccines.
The non-binding opinion, delivered in Luxembourg, represents a major victory for transparency advocates, European lawmakers, and civil society groups. By arguing that the public interest in contract transparency outweighs the commercial confidentiality of pharmaceutical companies, the court adviser has challenged the culture of executive secrecy in Brussels. As the European Union plans future joint procurement campaigns in healthcare and defense, this legal battle is establishing a permanent precedent for public accountability.
The Backstory: The Redacted Contracts of the Pandemic
The origins of the legal dispute trace back to the height of the global health crisis, when European governments scrambled to secure access to life-saving vaccines.
The Multi-Billion Procurement Campaign
During the chaotic early months of the pandemic, the European Commission, led by President Ursula von der Leyen, took responsibility for negotiating advance purchase agreements on behalf of the 27 EU member states.
The scale of the procurement campaign was unprecedented. The European Commission spent approximately €2.7 billion to secure roughly 1 billion doses of COVID-19 vaccines from several major pharmaceutical developers, including Pfizer, BioNTech, Moderna, and AstraZeneca.
While the coordinated purchasing campaign successfully prevented a bidding war among member states, the highly secretive manner in which the contracts were negotiated immediately sparked public concern.
The Green MEPs Step In
In January 2021, a group of five Green Members of the European Parliament, including Margrete Auken, Tilly Metz, Jutta Paulus, Kim van Sparrentak, and the late Michèle Rivasi, filed a formal request demanding full public access to the vaccine contracts and related documents.
They argued that because the Commission was spending billions of euros of public funds, citizens had a democratic right to know the terms, pricing, delivery schedules, and liability rules of the agreements.
The European Commission responded by releasing the contracts, but the documents were heavily redacted. Large swaths of text—including the cost per dose, delivery timelines, down payments, and liability protection rules—were completely blacked out.
Furthermore, the Commission refused to disclose the names and institutional roles of the individuals who made up the joint negotiation team, claiming that protecting their personal privacy under data protection rules was more important than public disclosure.
Faced with this heavy-handed censorship, the European lawmakers decided to take their case directly to the EU’s General Court.
The 2024 Lower Court Ruling and the Commission’s Counterattack
The legal battle has wound its way through the European court system for several years, resulting in a series of highly significant constitutional rulings.
The General Court’s Landmark Decision
A Reuters report recently highlighted that on July 17, 2024, the General Court of the European Union handed European lawmakers a partial but historic victory.
The lower court ruled that the European Commission did not provide the public with broad enough access to the vaccine purchase contracts.
The judges concluded that the Commission had failed to provide adequate justifications for redacting key passages of the contracts, particularly the indemnification and compensation clauses that protected drug companies from financial liability if the vaccines caused side effects.
The General Court also criticized the Commission’s refusal to disclose the names of the negotiation team.
The court ruled that only by having the names, surnames, and institutional roles of the negotiators could the public ascertain whether the members of the team had any conflicts of interest.
The ruling effectively annulled the Commission’s decision to keep these details hidden, ordering broader public disclosure.
The Commission’s Appeal and the March 2026 Hearing
Unwilling to accept the lower court’s decision, the European Commission quickly filed an appeal with the Court of Justice of the European Union, the bloc’s highest judicial authority.
The Commission argued that the lower court had misread the EU’s transparency rules and failed to properly weigh the commercial interests and intellectual property rights of the pharmaceutical companies involved.
During a high-stakes hearing in Luxembourg on March 4, the Commission’s legal representatives defended the redactions.
They told the judges that the contracts were negotiated under intense pandemic pressure and contained highly sensitive commercial provisions that were never meant to be made public.
The Commission warned that forcing the disclosure of these terms would damage the EU’s relations with private pharmaceutical companies, making it much harder for the bloc to secure critical medical supplies in future emergencies.
Decoding Rantos’ Opinion: Accountability over Secrecy
The latest phase of the legal battle took place when Advocate General Athanasios Rantos delivered his formal opinion on the case.
While the Advocate General’s recommendations are non-binding, the high court has historically followed his legal reasoning in the majority of cases.
The Public Interest in Negotiations
In his written conclusions, Rantos firmly supported the lower court’s reasoning and rejected the Commission’s arguments for secrecy.
He stated that the General Court was entirely correct in holding that the transparency of the process for negotiating COVID-19 vaccine agreements constitutes a specific purpose in the public interest under EU law.
Rantos argued that when public institutions negotiate major contracts on behalf of millions of citizens, transparency is not an optional luxury, but a core constitutional requirement.
Why Names and Roles Matter for Conflict of Interest
Rantos addressed the issue of negotiator privacy, rejecting the Commission’s attempt to use the General Data Protection Regulation to hide the identities of the joint negotiation team.
The Commission had argued that disclosing the negotiators’ names would expose them to unsolicited external contacts and violate their right to privacy.
The Advocate General concluded that the Commission’s approach did not permit concrete and effective verification of the negotiation team’s impartiality.
He argued that simply publishing anonymized declarations of conflict of interest, as the Commission had done, was insufficient to guarantee public trust.
Rantos ruled that the public has a legitimate interest in knowing the names and professional roles of the individuals spending public funds, as this is the only way to ensure that the negotiators do not have any conflicts of interest with the pharmaceutical companies.
The Shield of Indemnity Clauses
Rantos also rejected the Commission’s arguments regarding the redacted indemnification clauses.
During the pandemic, the Commission agreed to clauses that offered substantial liability protection to drug companies, effectively agreeing that EU member states would cover the legal costs and compensation claims if the vaccines caused side effects.
The Commission argued that publishing the details of these compensation rules would harm the commercial interests of the pharmaceutical companies.
Rantos dismissed this claim, concluding that the Commission had failed to prove that disclosing these indemnity rules would cause any real, foreseeable harm to the companies’ commercial interests.
He argued that because taxpayers are ultimately the ones funding these potential compensation claims, the public has an absolute right to know the terms and conditions under which their money is being committed.
Views: The Clash Between Corporate Confidentiality and Democratic Oversight
The ongoing legal battle has sparked a fierce debate among EU officials, legal scholars, and transparency advocates over where to draw the line between public oversight and commercial confidentiality.
The Institutional Defense of Emergency Procurement
Proponents of the European Commission’s position argue that in a global crisis, speed and confidentiality are essential to save lives.
They contend that during the pandemic, the Commission was engaged in a fierce global race to secure limited vaccine doses.
If negotiators had been forced to operate under the threat of immediate public exposure of every term, pharmaceutical companies might have refused to sign, or redirected their supplies to other countries, potentially leaving millions of Europeans without access to vaccines.
Supporters of this view argue that the Commission acted responsibly to protect both public health and the commercial confidentiality that private companies require to innovate.
They warn that if the high court forces complete disclosure, it will establish a dangerous precedent that will make private corporations highly reluctant to negotiate major supply contracts with the European Union in the future, damaging the bloc’s strategic security.
The Case for Public Trust and Democratic Safeguards
In contrast, transparency advocates and European lawmakers argue that complete openness is a fundamental democratic safeguard that must never be abandoned, even during emergencies.
They point out that hiding the identities of negotiators and the terms of multi-billion-euro contracts breeds public distrust, fuels conspiracy theories, and ultimately damages the credibility of public health campaigns.
Skeptics of the Commission’s secrecy argue that if the government is spending public funds and committing taxpayers to cover potential liability claims, there can be no justification for hiding those terms from the public.
They contend that the Commission’s refusal to disclose the names of the negotiation team makes it impossible to verify the impartiality of the procurement process.
From this perspective, the ruling is essential to restore public trust and ensure that future joint procurements are held to the highest standards of democratic accountability.
The Broader Precedent: Shaping the Future of EU Joint Procurement
The outcome of this case will have profound implications that extend far beyond the pandemic-era vaccine contracts.
Beyond the Pandemic: Defense and Health Security
The European Union is increasingly planning to use joint procurement campaigns to manage other major strategic challenges.
Member of the European Parliament Tilly Metz pointed out that this case is highly significant for the future, as the European Commission is expected to undertake more joint procurements in critical areas such as public health security and, potentially, joint defense and weapons purchasing.
If the high court rules that the Commission must disclose the details of its contracts, it will establish a permanent baseline for all future EU procurement campaigns.
EU institutions will no longer be able to use “crisis pressure” or “commercial confidentiality” as a blanket excuse to hide contract terms from the public.
Instead, they will be forced to operate under strict transparency rules, ensuring that future joint purchases of weapons, medical supplies, or technology are subject to rigorous public and parliamentary oversight.
Conclusion: The Final Verdict on Brussels’ Opacity
The Advocate General’s recommendation to dismiss the European Commission’s appeal represents a critical milestone for democratic accountability in Europe.
By prioritizing public interest and conflict-of-interest verification over administrative convenience and corporate confidentiality, the court adviser has sent a clear signal that Brussels must operate under the rule of law, even during times of global crisis.
While the Advocate General’s opinion does not legally bind the judges of the Court of Justice of the European Union, they are highly likely to follow his recommendations when they deliver their final, binding ruling later this year.
As the high court begins its final deliberations, the European Union stands on the verge of a historic decision that will either solidify public access to government contracts or allow the executive branch to continue shielding its decisions behind closed doors, proving that the struggle for transparency remains a defining challenge for the future of European democracy.
